Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Determinants of the efficacy of HIV latency-reversing agents and implications for drug and treatment design
Ruian Ke, Jessica M. Conway, David M. Margolis, Alan S. Perelson
Ruian Ke, Jessica M. Conway, David M. Margolis, Alan S. Perelson
View: Text | PDF
Research Article AIDS/HIV Therapeutics

Determinants of the efficacy of HIV latency-reversing agents and implications for drug and treatment design

  • Text
  • PDF
Abstract

HIV eradication studies have focused on developing latency-reversing agents (LRAs). However, it is not understood how the rate of latent reservoir reduction is affected by different steps in the process of latency reversal. Furthermore, as current LRAs are host-directed, LRA treatment is likely to be intermittent to avoid host toxicities. Few careful studies of the serial effects of pulsatile LRA treatment have yet been done. This lack of clarity makes it difficult to evaluate the efficacy of candidate LRAs or predict long-term treatment outcomes. We constructed a mathematical model that describes the dynamics of latently infected cells under LRA treatment. Model analysis showed that, in addition to increasing the immune recognition and clearance of infected cells, the duration of HIV antigen expression (i.e., the period of vulnerability) plays an important role in determining the efficacy of LRAs, especially if effective clearance is achieved. Patients may benefit from pulsatile LRA exposures compared with continuous LRA exposures if the period of vulnerability is long and the clearance rate is high, both in the presence and absence of an LRA. Overall, the model framework serves as a useful tool to evaluate the efficacy and the rational design of LRAs and combination strategies.

Authors

Ruian Ke, Jessica M. Conway, David M. Margolis, Alan S. Perelson

×

Figure 5

The proliferation rate is an important parameter determining reservoir size.

Options: View larger image (or click on image) Download as PowerPoint
The proliferation rate is an important parameter determining reservoir s...
(A) Antiproliferation therapy (left arrow) that reduces the proliferation rate below its baseline value (black vertical dashed line) would enhance LRA treatment and further increase the reservoir reduction (r.r.). The proliferation rate is set at the indicated values both during and after LRA treatment during a 10-dosing cycle as shown in Figure 2B. (B) The proliferation rate is set at the indicated values during LRA treatment only, and it is set to the baseline value 0.0072/day off LRA treatment. If an LRA off-target effect increases the proliferation rate (right arrow), the reservoir size will be reduced to a lesser extent, and the reservoir size may even increase (log10 r.r. < 0) if the increase in the proliferation rate is large enough. Colors denote the log10 reservoir reduction (log10 r.r.). Across the 2 panels, ‘×’ shows the baseline parameter values used (given in the caption for Figure 2). The dashed contour lines denote parameter combinations where no reduction in the size of the reservoir is achieved, i.e., log10 r.r. = 0.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts